 | David S ReasnerChester, Pa, Portland, Ore, and Marlborough, Mass | From aAsthma and Allergy Research Associates, Chester; bAllergy Associates, PC, Portland; and cSepracor Inc, Marlborough | ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
David S Reasner:Expert Impact
Concepts for whichDavid S Reasnerhas direct influence:Racemic albuterol,Levalbuterol racemic albuterol,Nebulized levalbuterol,Levalbuterol placebo,Racemic albuterol placebo,Patients levalbuterol,Treatment levalbuterol,Racemic albuterol treatment.
David S Reasner:KOL impact
Concepts related to the work of other authors for whichfor which David S Reasner has influence:Racemic albuterol,Acute asthma,Bronchodilator agents,Rac lev,Beta agonists,Allergic rhinitis.
KOL Resume for David S Reasner
| Year | |
|---|---|
| 1999 | Chester, Pa, Portland, Ore, and Marlborough, Mass From aAsthma and Allergy Research Associates, Chester; bAllergy Associates, PC, Portland; and cSepracor Inc, Marlborough |
| 1998 | Denver, Colo, Stockton and Encinitas, Calif, Wilmington, NC, and Marlborough, Mass |
| Concept | World rank |
|---|---|
| levalbuterol greater | #2 |
| conclusion levalbuterol | #2 |
| levalbuterol plasma | #2 |
| nebulized beta2 agonists | #2 |
| levalbuterol plasma levels | #2 |
| polgars values | #2 |
| efficacy nebulized levalbuterol | #2 |
| placebo fev1 values | #2 |
| limited doseresponse | #2 |
| xopenex | #3 |
| levalbuterol 031 | #3 |
| 4 treatment visits | #3 |
| treatment levalbuterol | #4 |
| 125 racemic | #4 |
| 063 racemic | #4 |
| levalbuterol patients | #5 |
| racemic albuterol placebo | #5 |
| combined racemic | #6 |
| levalbuterol compared | #7 |
| levalbuterol 063 | #7 |
| racemic albuterol patients | #8 |
| doses levalbuterol | #8 |
| albuterol racemic | #8 |
| racemic albuterol treatment | #8 |
| received levalbuterol | #9 |
| levalbuterol 125 | #9 |
| levalbuterol placebo | #11 |
| albuterol 125 | #12 |
| 25 racemic | #14 |
| levels albuterol | #15 |
| dose levalbuterol | #15 |
| levalbuterol administered | #17 |
| received racemic | #18 |
| patients levalbuterol | #19 |
| nebulized levalbuterol | #20 |
| albuterol beta | #24 |
| levalbuterol racemic albuterol | #26 |
| albuterol levels | #30 |
| levalbuterol albuterol | #31 |
| albuterol 25 | #33 |
| levalbuterol racemic | #37 |
| asthma pediatric patients | #40 |
| 031 063 | #43 |
| albuterol compared | #51 |
| enantiomer levels | #51 |
| levalbuterol | #63 |
| compared racemic | #68 |
| doses nebulized | #70 |
| 063 125 | #72 |
| racemic albuterol | #91 |
Prominent publications by David S Reasner
BACKGROUND: Limited dose-response information is available for nebulized beta2 -agonists, especially in young children.
OBJECTIVE: The purpose of this study was to determine the safety and efficacy of increasing doses of nebulized levalbuterol (Xopenex; the pure R-isomer of racemic albuterol) and racemic albuterol compared with placebo in the treatment of asthma in pediatric patients.
METHODS: In this randomized, double-blind, crossover study, children (aged 3 to 11 years) with asthma ...
| Known for Nebulized Levalbuterol | Pediatric Patients | Racemic Albuterol | Treatment Asthma | Placebo Fev1 |
Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma
[ PUBLICATION ]
BACKGROUND: Racemic albuterol is an equal mixture of (R)-albuterol (levalbuterol), which is responsible for the bronchodilator effect, and (S)-albuterol, which provides no benefit and may be detrimental.
OBJECTIVE: We sought to compare 2 doses of a single enantiomer, levalbuterol (0.63 mg and 1.25 mg), and equivalent amounts of levalbuterol administered as racemic albuterol with placebo in patients with moderate-to-severe asthma.
METHODS: This was a randomized, double-blind, ...
| Known for Racemic Albuterol | Placebo Patients | 4 Weeks | Asthma Bronchodilator | Primary Endpoint |
